Art of the Question
Carel le Roux is a Professor of Experimental Pathology at University College Dublin, Director of the Metabolic Medicine Group, and one of the world's leading researchers on how the gut communicates with the brain. He completed his PhD at Imperial College London, where he conducted foundational research on gut hormones and appetite, and later co-founded My Best Weight, Ireland's leading obesity care clinic accredited by the European Association for the Study of Obesity. His clinical work and trials span GLP-1 receptor agonists, bariatric surgery outcomes, and the emerging class of multi-receptor drugs now transforming obesity medicine. He is currently leading the trial of survodutide, one of the most promising next-generation treatments in the field. Expect to learn how GLP-1 was discovered during PhD research into gut-brain communication and how it became one of the most consequential drug classes in medical history, what the Gila monster's saliva has to do with the development of Ozempic and drugs like it, why obesity is a disease of the brain rather than a failure of willpower or lifestyle, how these medications reset the brain's fat-mass setpoint so that weight loss happens without deliberate effort, what ultra-processed foods may be doing to brain inflammation and why reversing the obesity epidemic through diet advice alone has failed everywhere it has been tried, why the goal of treatment should be health gain rather than weight loss and what that distinction means in practice, how to manage and minimise side effects by titrating the dose slowly, what the long-term safety record of GLP-1 drugs actually shows and why not taking the medication is often the riskier choice, why muscle loss on these drugs is largely a misunderstood phenomenon and what protein intake and exercise do to address it, what the evidence says about non-obese people using GLP-1 drugs recreationally and why these treatments were designed as lifelong medications, how GLP-1-like drugs appear to reduce alcohol consumption and are now being studied for addiction and other conditions including heart and kidney disease, and what new triple-receptor drugs like retatrutide and survodutide offer over existing treatments. Carel le Roux online: Website: mybestweight.ie [http://mybestweight.ie] University profile: University College Dublin, Conway Institute of Biomolecular and Biomedical Research
26 Folgen
Kommentare
0Sei die erste Person, die kommentiert
Melde dich jetzt an und werde Teil der Art of the Question-Community!